Phase II study of S-1 monotherapy as a first-line, combination therapy of S-1 plus cisplatin as a second-line, and weekly paclitaxel monotherapy as a third-line therapy in patients with advanced gastric carcinoma: Phase II Study of S-1, S-1 plus cisplatin, and weekly paclitaxel in patients with advanced gastric carcinoma

Clinical Medicine: Oncology

Volumn 2, Issue , 2008, Pages 375-383

  Rino, Yasushi ^a   Yukawa, Norio ^a   Wada, Nobuyuki ^a   Suzuki, Makoto ^a   Murakami, Hitoshi ^a   Yamada, Takanobu ^a   Nakayama, Hirotaka ^a   Yamamoto, Naoto ^b   Sato, Tsutomu ^b   Yamada, Roppei ^b   Ohshima, Takashi ^b   Masuda, Munetaka ^a   Imada, Toshio ^c  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^c YOKOHAMA CITY UNIVERSITY HOSPITAL   (Japan)

Author keywords

Advanced gastric cancer; Cisplatin; First line chemotherapy; Paclitaxel; Phase II study; Recurrent gastric cancer; S 1; Second line chemotherapy; Third line chemotherapy

Indexed keywords

EID: 77951497606     PISSN: None     EISSN: 11779314     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Preusser, P., Wilke, H., Achterrath, W., Fink, U., Lenaz, L., Heinicke, A., Meyer, J., Meyer, H.J. and Buente, H. 1989. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J. Clin. Oncol., 7:1310-7.
2. Cocconi, G., Bella, M., Zironi, S., Algeri, R., Costanzo, F.D., Lisi, V.D., Luppi, G., Mazzocchi, B., Rodino, C., Soldani, M., Gilli, G. and Finard, C. 1994. Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer; a prospective randomized trial of the Italian Oncology Group for Clinical Research. J. Clin. Oncol., 12:2687-93.
3. Ota, K., Taguchi, T. and Kimura, K. 1988. Report on nationalwide pooled data and cohort investigation in UFT Phase II study. Cancer Chemother. Pharmacol., 22:333-8.
4. Shirasaka, T., Nakano, K., Takechi, T., Satake, H., Uchida, J., Fujioka, A., Saito, H., Okabe, H., Oyama, K., Takeda, S., Unemi, N. and Fukushima, M. 1996. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyrimidine-1 M potasium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res., 56:2602-6.
5. Fukushima, M., Satake, H., Uchida, J., Shimamoto, Y., Kato, T., Takechi, T., Okabe, H., Fujioka, A., Nakano, K., Ohshimo, H., Takeda, S. and Shirasaka, T. 1998. Preclinical antitumor efficacy of S-1; a new oral formulation of 5-fluorouracil on human tumor xenografts. Int. J. Oncol., 13:693-8.
6. Sugimachi, K., Maehara, Y., Horikoshi, N., Shimada, Y., Sakata, Y. and Taguchi, T. 1999. The S-1 Gastrointestinal Cancer Study Group: An early phase II study of oral S-1, a newly developed 5-fluoruracil derivative for advanced and recurrent gastrointestinal cancers. Oncology, 57:202-10.
7. Sakata, Y., Ohtsu, A., Horikoshi, N., Sugimachi, K., Mitachi, Y. and Taguchi, T. 1998. Late phase II study of novel oral fluoropyrimidineanticancer drug S-1 (1 M tegafur-0.4 M Gimestat-1 M otastat potasium) in advanced gastric cancer patients. Eur. J. Cancer, 34:1715-20.
8. Hirata, K., Horikoshi, N., Aiba, K., Okazaki, M., Denno, R., Sasaki, K., Nakano, Y., Ishizuka, H., Yamada, Y., Uno, S., Taguchi, T. and Shirasaka, T. 1999. Pharmakokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin. Cancer Res., 5:2000-5.
9. Koizumi, W., Kurihara, M., Nakano, S. and Hasegawa, K. 2000. The S-1 gastrointestinal cancer study group: Phase II study of S-1, a novel derivative 5-fluorouracil, in advanced gastric cancer. Oncology, 58:191-7.
10. Maehara, Y. 2003. S-1 in gastric cancer: a comprehensive review. Gastric Cancer, 6(Suppl 1):2-8.
11. Koizumi, W., Tanabe, S., Saigenji, K., Ohtsu, A., Boku, N., Nagashima, F., Shirao, K., Matsumura, Y. and Gotoh, M. 2003. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br. J. Cancer, 89(12):2207-12.
12. Chung, Y., Yamashita, Y., Inoue, T., Matsuoka, T., Nakata, B., Onoda, N., Maeda, K., Sawada, T., Kato, Y., Shirasaka, T. and Sowa, M. 1997. Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Cancer, 80:1-7.
13. Kim, R., Nishimoto, N., Inoue, H., Yoshida, K. and Toge, T. 2000. Ananalysis of the therapeutic efficacy of protracted infusion of lowdose 5- fluorouracil and cisplatin in advanced gastric cancer. J. Infect. Chemother., 6:222-8.
14. Cadman, E., Heiner, R. and Benz, C. 1981. The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells. J. Biol. Chem., 25:1695-704.
15. Mori, T., Fujiwara, Y., Yano, M., Tamura, S., Yasuda, T., Takiguchi, S. and Monden, M. 2003. Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer. Gastric Cancer, 6(Suppl 1):13-18.
16. Nagashima, F., Ohtsu, A., Yoshida, S. and Ito, K. 2005. Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer. Gastric Cancer, 8(1):6-11.
17. Ohshima, T., Yamada, R., Hatori, S., Kunisaki, C., Makino, T., Yamazaki, Y., Suda, T., Rino, Y., Takanashi, Y. and Imada, T. 2006. [Clinical results of single therapy with TS-1 for advanced/recurrent gastric cancer]. Gan To Kagaku Ryoho, 33(8):1105-10. Japanese.
18. Sakaguchi, Y., Kabashima, A., Okita, K., Ojima, Y., Yamamura, S., Nishizaki, T., Tashiro, H. and Matsusaka, T. 2005. Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer. Gastric Cancer, 8(2):111-6.
19. Maeda, S., Saikawa, Y., Kubota, T., Aoki, M., Otani, Y., Furukawa, T., Watanabe, M., Kumai, K. and Kitajima, M. 2003. No cross-resistance of taxotere and taxol to conventional chemotherapeutic agents against gastric cancers as detected by MTT assay. Anticancer Res., 23(4):3147-50.
20. Fennelly, D., Aghajanian, C., Shapiro, F., O'Flaherty, C., McKenzie, M., O'Connor, C., Tong, W., Norton, L. and Spriggs, D. 1997. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J. Clin. Oncol., 15(1):187-92.
21. Kim, R., Osaki, A. and Toge, T. 2001 Sep-Oct. Pharmacokinetic and biochemical analysis in the treatment of weekly paclitaxel in relapsed breast cancer. Oncol. Rep, 8(5):1171-6.
22. Choy, H., Akerley, W., Safran, H., Clark, J., Rege, V., Papa, A., Glantz, M., Puthawala, Y., Soderberg, C. and Leone, L. 1994. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J. Clin. Oncol., 12(12):2682-6.
23. Hatori, S., Kunisaki, C., Ono, H., Sato, T., Otsuka, Y., Yamada, R., Ohshima, T., Rino, Y. and Imada, T. 2006. Clinical efficacy and safety of weekly paclitaxel therapy as second-line chemotherapy for patients with advanced and recurrent gastric cancer who were previously treated with TS-1 therapy. Gan To Kagaku Ryoho, 33(9):1257-60.
24. Kii, T., Takiuchi, H., Gotoh, M., Kawabe, S., Ohta, S., Tanaka, T., Kuwakado, S., Nishitani, H. and Katsu, K. 2006. Weekly administration regimen of paclitaxel (PTX) in patient with inoperable or recurrent gastric cancer]. Gan To Kagaku Ryoho, 33(5):621-4. Japanese.
25. Egawa, T., Kubota, T., Nagashima, A., Doi, M., Kitano, M., Hayashi, S., Yoshii, H., Saikawa, Y. and Kitajima, M. 2004. Usefulness of weekly administration of paclitaxel for advanced or recurrent gastric cancer. Gan To Kagaku Ryoho, 31(6):877-81. Japanese.